生物制剂在克罗恩病合并肛周瘘管治疗中的应用  

Application of Biological Agents in Treatment of Perianal Fistulizing Crohn 's Disease

作　　者：严笑寒 朱明明[1] 徐锡涛[1] 冉志华[1] YAN Xiaohan;ZHU Mingming;XU Xitao;RAN Zhihua(Division of Gastroenterology and Hepatology,Renji Hospital,School of Medicine,Shanghai Jiao Tong Universit;Shanghai Institute of Digestive Diseas;Shanghai Inflammatory Bowel Disease Research Center,Shanghai,20000)

机构地区：[1]上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所上海市炎症性肠病研究中心,200001

出　　处：《胃肠病学》2018年第10期626-629,共4页Chinese Journal of Gastroenterology

基　　金：国家自然科学青年基金(81302092)

摘　　要：克罗恩病合并肛周瘘管(pfCD)常预示疾病为进展型、难治型亚型。2/3的pfCD患者会复发,因此治疗极具难度。近年来生物制剂的研究取得长足进展,英夫利西单抗等生物制剂的临床应用给pfCD的治疗带来新希望。本文就生物制剂在pfCD治疗中的应用作一综述。Perianal fistulizing Crohn’s disease （pfCD） often indicates aggressive and refractory phenotype. Two-thirds of the patients with pfCD will relapse, so the treatment is really challenging. Currently, biological agents have made great progress. The application of biological agents such as infliximab brings new hope to the treatment of pfCD. This article reviewed the application of biological agents in treatment of pfCD.

关 键 词：CROHN病 肛瘘 生物制剂 治疗 

分 类 号：R574.62[医药卫生—消化系统] R574.8[医药卫生—内科学]